Sequent Scientific Ltd (BSE: 512529) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Research Organization industry. With a market capitalisation of ₹11,186 Cr, it ranks #562 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹258.90 (as of 16 Nov 2026), the share price is 13.1% below its 52-week high of ₹298.00 and 45.3% above its 52-week low of ₹178.13. The share price is up 18.9% over one year and down 4.1% over three months.
| Current Price | ₹258.90 |
|---|---|
| Market Cap | ₹11,186 Cr |
| BSE Code | 512529 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Research Organization |
| P/E Ratio | 63.5 |
| Return on Equity | 11.56% |
| Return on Assets | 6.00% |
| 52-Week Range | ₹178.13 – ₹298.00 |
| 1-Year Price Change | +18.9% |
| 3-Month Price Change | -4.1% |
| Beta (1Y) | 0.44 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.sequent.in |
| Revenue | ₹988 Cr |
|---|---|
| Net Profit | ₹85 Cr |
| Net Margin | 8.6% |
| EPS (Basic) | ₹1.74 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sequent Scientific Ltd reported revenue of ₹988 Cr in Q2 FY27, up 133.0% from ₹424 Cr in Q2 FY26 and up 4.4% from ₹946 Cr in Q1 FY27. It posted a net profit of ₹85 Cr for the quarter, against a net profit of ₹20 Cr in Q2 FY26 (up 331.9%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹402 Cr (Q4 FY25) to ₹988 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹988 Cr | ₹85 Cr | 8.6% |
| Q1 FY27 | ₹946 Cr | ₹79 Cr | 8.4% |
| Q4 FY26 | ₹920 Cr | ₹66 Cr | 7.2% |
| Q3 FY26 | ₹858 Cr | ₹49 Cr | 5.7% |
| Q2 FY26 | ₹424 Cr | ₹20 Cr | 4.6% |
| Q1 FY26 | ₹441 Cr | ₹18 Cr | 4.0% |
| Q4 FY25 | ₹402 Cr | ₹10 Cr | 2.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 49.24% of Sequent Scientific Ltd's shares as of Sept 2026, against 52.33% in Sept 2025 (−3.09 percentage points). Delivery averaged 49.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as PI Drugs & Pharmaceuticals Ltd. and changed its name to Sequent Scientific Limited in October 2009. The company was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited is a subsidiary of CA Harbor Investments.
1. Pharmaceuticals-This segment offers pharmaceutical products that are related to animal health. 2. Segment Adjustment-0 3. Analytical Services-This segment provides analytical and bio-analytical services primarily to pharmaceutical and consumer product companies. 4. Unallocated-This segment engages in woman healthcare business. It provides pharmaceutical products.
1. Pharmaceuticals-100%
Sequent Scientific Ltd is trading at ₹258.90, with a market capitalisation of ₹11,186 Cr.
Sequent Scientific Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Research Organization).
Sequent Scientific Ltd has a P/E of 63.5 and a return on equity of 11.56%.
Sequent Scientific Ltd is listed on the BSE under the scrip code 512529.
Sequent Scientific Ltd's share price is up 18.9% over one year and down 4.1% over three months. Its 52-week range is ₹178.13 to ₹298.00.
In Q2 FY27, Sequent Scientific Ltd reported revenue of ₹988 Cr and net profit of ₹85 Cr, with basic EPS of ₹1.74 (consolidated, parsed from the company's exchange filing).
Sequent Scientific Ltd reported revenue of ₹988 Cr in Q2 FY27, up 133.0% from ₹424 Cr in Q2 FY26 and up 4.4% from ₹946 Cr in Q1 FY27.
Promoters held 49.24% of Sequent Scientific Ltd's shares as of Sept 2026, against 52.33% in Sept 2025 (−3.09 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.